Prostate-specific antigen (PSA) is a biomarker for prostate cancer diagnosis and screening. Moreover, PSA is also the first cancer biomarker approved. In recent years, CD BioGlyco has made many advances in detecting glycobiomarkers in minimally invasive samples that can help researchers more accurately predict disease progression.

PSA

Cancer is the primary cause of death in both developing and developed countries. Prostate cancer is the most commonly diagnosed cancer in men, with the incidence expected to increase to 2.1 million by 2035 and the associated deaths to 633,328. The survival rate is proportionate to the stage reached at diagnosis, making early diagnosis by effective and disruptive diagnostic method critical to reducing mortality.

PSA is a serine protease generated by prostate epithelial cells, and the main function of PSA is to liquefy seminal coagulum. The amount and serum subtype of male PSA can distinguish between prostate cancer and benign inflammatory disease. In women, the expression of this glycoprotein is highly correlated with breast and colon cancers. Thus, PSA can function as a tumor biomarker and can be a powerful tool for a wide range of prostate cancer screening and early detection, diagnosis and prognostic screening of breast and colon cancers in women.

Techniques

CD BioGlyco has developed a variety of promising analytical tools to detect glyco-biomarker PSA for an early diagnosis of prostate cancer. The techniques we provide include but are not limited to:

• We employ multiple immunostrip (immunochromatographic membrane or lateral flow) tests to provide point-of-care testing (POCT) for PSA. The results could be obtained in minutes, meaning the possibility of requiring fewer clinical visits and providing better clinical results.
• We employ small footprint microarray technologies, which can capture a wide range of proteins. This system uses a combination of enzyme markers and magnetic particles to provide highly sensitive detection of a wide range of substances including PSA, platelet factor 4 (PF-4), prostate-specific membrane antigen (PSMA) and interleukin 6 (IL-6).
• Instrument-based and lectin-based methods are also employed for PSA glycoprofiling, which can be used as diagnostic or prognostic biomarkers of prostate cancer.

PSA Testing: Decoding the Biological Code of Prostate Cancer Development

• Glycosylation analysis: We provide PSA glycosylation pattern analysis services, leveraging glycosylation-specific markers (like lectins) and advanced methodologies, including enzyme-linked immunosorbent assay (ELISA), mass spectrometry (MS), etc.
• PSA glycosylation characteristics: We offer professional PSA glycosylation characteristic testing services, including core fucosylation, sialylation, etc.
• Qualitative and quantitative: Using matrix-assisted laser desorption/ionization time-of-flight mass (MALDI-TOF MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), we offer highly sensitive and accurate polysaccharide qualitative and quantitative services.
• We provide detailed reports on the identified glycan structures and their relative abundance.

Workflow

Applications

• Tumor tissues exhibit distinct PSA glycosylation profiles compared to their normal counterparts. Through the study of PSA's glycosylation features, the researchers can determine if it comes from normal prostate cells or prostate cancer, contributing valuable insights to cancer research.
• We help clients detect the progression and malignancy of prostate cancer by analyzing PSA glycosylation patterns, such as increases in neutral sugar chains, changes in salivary acidification patterns, and enhanced fucosylation.
• To boost the accuracy and sensitivity of cancer monitoring, our top-tier PSA testing is utilized alongside additional biomarkers, including prostatic acid phosphatase (PAP), free PSA (fPSA), etc.

Advantages of Us

• We have advanced tools, mature operating procedures, and experienced operators to ensure rapid project progress.
• We offer customized solutions based on client needs. For example, we not only offer PSA testing but also provide novel biomarker discovery and validation services.
• The primary strength of our approach is its ability to more effectively distinguish malignant prostate cancer from benign conditions. This comes from the superior specificity and sensitivity gained by analyzing PSA glycosylation patterns, a significant improvement over using total PSA alone.

Publication Data

Frequently Asked Questions

At CD BioGlyco, our Glyco-biomarker PSA Detection Service combines cutting-edge glycoanalysis technologies with deep scientific expertise to deliver accurate and sensitive detection of PSA glycoforms. Designed to advance cancer research and clinical biomarker development, our tailored solutions provide reliable data to support your specific project needs. Please contact us today to learn how we can accelerate your success.

Associated Services